admin

Shares of Cannabis Sativa Inc (OTCMKTS:CBDS) exploded up the charts on the back of positive news from GW Pharmaceuticals plc (NASDAQ:GWPH). GWPH announced positive results in a Phase 3 clinical trial assessing Orphan Drug- and Fast Track-tagged Epidiolex (cannabidiol) for the treatment of Dravet syndrome, a rare and catastrophic form of childhood epilepsy for which there are no […]

by

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, […]

by

The FDA designates Zynerba Pharmaceuticals’ (ZYNE +2%) ZYN002 cannabidiol gel an Orphan Drug for the treatment of Fragile X syndrome, a genetic disorder characterized by learning disabilities and cognitive impairment. ZYN002 is designed to deliver a controlled dose of cannabidiol transdermally via a permeation-enhanced gel formulation. A Phase 2 study should commence by year end. […]

by

TYLER, TX — (Marketwired) — 02/24/16 — Wisdom Homes of America, Inc. (the “Company”) (OTC PINK: WOFA) concentrates on licensing products and technology benefiting the cannabis patient and consumers. The Company is proud to announce that it has contracted with Healthy Asylum, Inc., a manufacturer of oral strips including CannaStrips. Healthy Asylum has completed an […]

by

PHILADELPHIA — In the largest study of its kind, researchers report that Epidiolex, a pharmaceutical-grade, purified form of cannabidiol, is generally well-tolerated and is a promising treatment for treatment-resistant epilepsies. The results, from the open-label Expanded Access treatment programs from 16 sites, were presented at the 2015 American Epilepsy Society Annual Meeting in Philadelphia. Epidiolex, […]

by